GuruFocus.com
Versant Venture Management, LLC Buys Veracyte Inc
GuruFocus.com

In This Article:

- By insider

San Francisco, CA, based Investment company Versant Venture Management, LLC buys Veracyte Inc during the 3-months ended 2018-09-30, according to the most recent filings of the investment company, Versant Venture Management, LLC. As of 2018-09-30, Versant Venture Management, LLC owns 9 stocks with a total value of $294 million. These are the details of the buys and sells.

  • New Purchases: VCYT,

  • Added Positions: CBAY,


For the details of Versant Venture Management, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Versant+Venture+Management%2C+LLC

These are the top 5 holdings of Versant Venture Management, LLC

  1. CRISPR Therapeutics AG (CRSP) - 3,608,874 shares, 54.48% of the total portfolio.

  2. Audentes Therapeutics Inc (BOLD) - 1,204,615 shares, 16.23% of the total portfolio.

  3. Veracyte Inc (VCYT) - 3,616,221 shares, 11.75% of the total portfolio. New Position

  4. Ocular Therapeutix Inc (OCUL) - 2,215,384 shares, 5.19% of the total portfolio.

  5. CymaBay Therapeutics Inc (CBAY) - 1,084,696 shares, 4.09% of the total portfolio. Shares added by 3.44%

New Purchase: Veracyte Inc (VCYT)

Versant Venture Management, LLC initiated holding in Veracyte Inc. The purchase prices were between $9.55 and $12.64, with an estimated average price of $11.03. The stock is now traded at around $9.31. The impact to a portfolio due to this purchase was 11.75%. The holding were 3,616,221 shares as of 2018-09-30.



Here is the complete portfolio of Versant Venture Management, LLC. Also check out:


1. Versant Venture Management, LLC's Undervalued Stocks

2. Versant Venture Management, LLC's Top Growth Companies, and

3. Versant Venture Management, LLC's High Yield stocks

4. Stocks that Versant Venture Management, LLC keeps buyingThis article first appeared on GuruFocus.


Terms and Privacy Policy
Your Privacy Choices
Utah Privacy Notice
More Info

Recommended Stories